+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Histamine on Basal and TRH/LH-RH-Stimulated PRL and LH Secretion during Different Phases of the Menstrual Cycle in Normal Women

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The neurotransmitter histamine (HA) may participate in the regulation of some pituitary hormones. We, therefore, investigated the effect of HA (50 µg/kg body weight/h, infusion 0–240 min) on basal and thyrotropin-releasing hormone (TRH) and luteinizing hormone releasing hormone (LH-RH) stimulated prolactin (PRL) and LH secretion in 5 normal women during the early follicular and the luteal phases of the same menstrual cycle. HA had no effect on the basal secretion of the two hormones. However, the PRL response to 200 µg TRH during the HA infusion was significantly increased compared to the response to a saline control infusion during the early follicular phase (peak responses were 1,902 ± 398 vs. 1,228 ± 230 µlU/ml, p < 0.025) and during the luteal phase (peak responses were 2,261 ± 335 vs. 1,647 ± 245 µlU/ml, p < 0.05). HA potentiated the LH response to 100 µg LH-RH during the early follicular phase (peak responses were 37.1 ± 4.9 vs. 26.9 ± 4.5 mlU/ml, p < 0.05) and during the luteal phase (peak responses were 79.3 ± 22.5 vs. 50.7 ± 11.4 mlU/ml, p < 0.025). We, therefore, found HA to have a potentiating effect on TRH/LH-RH-stimulated PRL and LH secretion in women. The results are similar to our previous findings in men, although the potentiating effects of HA were higher in women.

          Related collections

          Author and article information

          S. Karger AG
          28 March 2008
          : 41
          : 4
          : 337-341
          Department of Surgical Gastroenterology, Hvidovre Hospital, University of Copenhagen, and Hormone Department, Statens Seruminstitut, Copenhagen, Denmark
          124198 Neuroendocrinology 1985;41:337–341
          © 1985 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper


          Comment on this article